J. Goldman & Co’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

J. Goldman & Co’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-970,584	Closed	-$4.08M	–	536
2023 Q1	$4.08M	Buy	970,584 +333,664	+52%	+$1.73M	0.17%	159
2022 Q4	$3.83M	Buy	636,920 +372,507	+141%	+$2.03M	0.19%	122
2022 Q3	$1.54M	Sell	264,413 -103,165	-28%	-$643K	0.07%	229
2022 Q2	$2.19M	Buy	367,578 +296,235	+415%	+$1.52M	0.11%	196
2022 Q1	$333K	Buy	+71,343	New	+$213K	0.02%	306

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

J. Goldman & Co's CTIC Position: Q2 2023 in Review

J. Goldman & Co sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 970,584 shares — an estimated $4.08M sold.

J. Goldman & Co first reported a position in CTIC in Q1 2022 and held it in 5 quarters. The position peaked at $4.08M in Q1 2023. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

J. Goldman & Co reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
J. Goldman & Co sold 970,584 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $4.08M.
J. Goldman & Co first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2022 and held it in 5 quarters.
J. Goldman & Co's CTI BioPharma Corp. (DE) Common Stock position peaked at $4.08M in Q1 2023.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on J. Goldman & Co's 13F filing for Q2 2023, filed 14 Aug 2023.